Omeros soars on single Phase III plan for OMS721

Omeros Corp. (NASDAQ:OMER) soared $4.08 (29%) to $18.17 Friday after announcing late Thursday that FDA will accept a single Phase III trial with a primary endpoint of proteinuria reduction to support approval of OMS721 to treat IgA nephropathy. Omeros plans to start the trial this year.

The company said there are no approved treatments for IgA nephropathy...